OnaBotulinumtoxin-A in Chronic Migraine Patients With Short or Long Disease History (the BACH Study)
OnaBotulinumtoxin-A Effectiveness Evaluation in Chronic Migraine Patients With Short or Long Disease History: an Italian Multicentric Study (the BACH Study)
Fondazione Policlinico Universitario Campus Bio-Medico
115 participants
Jan 1, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this observational prospective multicentric study, 12 months duration is to investigate whether the history of Chronic Migraine and, more precisely, its duration for over or less than 10 years, can predict OBT-A treatment effectiveness. Since CM patients may have a complex psychopathological profile and psychiatric symptoms represent a bad prognostic factor influencing treatment effectiveness, the present study will also aim at evaluating if the psychopathological profile of the enrolled patients may influence the outcome.
Eligibility
Inclusion Criteria3
- Age between 18 and 70 years-old
- Chronic Migraine defined according to 1.3 ICHD-3
- Informed consent
Exclusion Criteria4
- secondary headache
- Onabotulinumtoxin-A in the previous 3 months
- pregnancy or breastfeeding
- detoxification protocol for Medication Overuse Headache in the last 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06537700